Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 6Completed 6Not yet recruiting 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Uterine Cervical Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Small Cell Lung Cancer Limited Stage 1Radiotherapy 1Liver Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Tumours 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1

Interventions

Injections 3pembrolizumab 2olaparib 2atezolizumab 2Leucovorin 2Irinotecan 2ulixertinib 1toripalimab 1tipifarnib 1sotorasib 1serabelisib 1mirdametinib 1famitinib 1camrelizumab 1adagrasib 1Taxes 1Ramucirumab 1Radiation 1Paclitaxel 1IFL protocol 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Fluorouracil 1Docetaxel 1Bevacizumab 1BID protein, human 1Appointments and Schedules 1Albumin-Bound Paclitaxel 1APG-1387 15-fluorouridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Tumor × toripalimab × Clear all
NCT04284488 2026-01-08

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Ascentage Pharma Group Inc.

Phase 1/2 Terminated
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡